指南与共识特殊人群用药治疗药物监测与药物基因组学抗栓抗凝管理

CYP2C19基因检测指导氯吡格雷用药:英国CERSI-PGx指南解读

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).
指南 / 共识 · Br J Clin Pharmacol · 2025-12-03

该指南由英国CERSI-PGx制定,指出氯吡格雷需CYP2C19代谢活化,携带功能缺失等位基因者疗效降低或缺失。建议所有拟用氯吡格雷者尽可能检测CYP2C19,中间或慢代谢型应避免使用并选替代方案。

要点

  • 氯吡格雷需CYP2C19活化,功能缺失等位基因降低或消除疗效。
  • 拟用氯吡格雷者应尽可能检测CYP2C19以优化抗血小板治疗。
  • 中间或慢代谢型应避免氯吡格雷,所有适应症均选替代方案。

核心结论

  • 氯吡格雷在CYP2C19中间或慢代谢型患者中临床有效性降低或缺失。
  • 所有拟用氯吡格雷者,无论适应症,有条件应检测CYP2C19以优化抗血小板治疗。
  • 中间或慢代谢型患者在所有获批适应症中应避免氯吡格雷,改用指南详述的替代方案。

研究设计与样本

  • 该指南由英国监管科学与创新卓越中心药物基因组学部门(CERSI-PGx)制定。

主要发现

  • CYP2C19基因多态性可消除、降低或增加酶活性,影响氯吡格雷转化为活性代谢物。
  • 携带一个或两个功能缺失等位基因者分别称为中间代谢型和慢代谢型。
  • 中间和慢代谢型患者中氯吡格雷临床有效性降低或缺失。

关键数值与推荐

  • 拟用氯吡格雷者,无论基础适应症,在有条件时应进行药物基因组检测以识别临床相关CYP2C19变异。
  • 中间或慢代谢型患者在所有获批适应症中应避免使用氯吡格雷。
  • 替代治疗方案详见指南正文(Boxes 1-3提供各适应症一页摘要指导)。

临床怎么用

  • 处方氯吡格雷前,若有条件应检测CYP2C19基因型以识别中间或慢代谢型。
  • 中间或慢代谢型患者应避免氯吡格雷,并按指南选择替代抗血小板方案。
  • 处方者需全面评估每位患者风险获益,优化治疗以最大化获益并最小化危害。

局限性

  • 指南基于最新证据,但无法涵盖所有与患者护理相关的个体因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective. CYP2C19 is encoded by a polymorphic gene; variants in the CYP2C19 gene, which vary in frequency in different ethnic groups can abolish, reduce or increase enzyme activity, thereby affecting the conversion of clopidogrel to its active metabolite. Individuals who have either one or two loss-of-function alleles are referred to as intermediate and poor metabolisers, respectively, and in these patients, the clinical effectiveness of clopidogrel is reduced or absent. Any patient about to be prescribed clopidogrel, regardless of the underlying indication, should have pharmacogenetic testing to identify clinically relevant CYP2C19 variants, where testing is available, to optimize their antiplatelet therapy. Clopidogrel use should be avoided in patients with an intermediate or poor CYP2C19 metaboliser phenotype in all approved indications and alternative treatment regimens used as detailed in this guideline. Our guideline is compatible with other international pharmacogenetic prescribing guidelines, but we also provide recommendations in other areas. Summary guidance on a page is provided for each of the indications in Boxes 1-3. This guideline is grounded in the latest evidence in this field but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk-benefit profile, ensuring that therapy is optimized to maximize benefits while minimizing potential harms.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Dello Russo C, Frater I, Kuruvilla R, et al. CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). Br J Clin Pharmacol. 2025. PMID: 41338248. doi:10.1002/bcp.70370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。